Lake B G, Phillips J C, Heading C E, Gangolli S D
Toxicology. 1976 Mar;5(3):297-309. doi: 10.1016/0300-483x(76)90049-4.
The biotransformation of dimethylnitrosamine (DMN) to formaldehyde, generally attributed to the mediation of a demethylase enzyme associated with the microsomal mixed function oxidase system, has been investigated in rat liver preparations. All of the enzyme activity was found in the postmitochondrial fraction and the microsomes contained approximately 50% of this activity. The restoration of total activity resulting from the addition of the cytosol to the microsomal fraction was found to be due to presence of diffusible, heat-labile constituents in the cytosol. Enzyme kinetic studies revealed that DMN was metabolized to formaldehyde by either a multistep or a multicomponent process. DMN demethylase was found to be relatively stable to storage in contrast to cytochrome P-450 and a number of mixed function oxidase enzyme activities. In spectral interaction studies DMN was found to form an atypical interaction spertrum with either control, phenobarbitone-pretreated or phospholipid-depted microsomal preparations. DMN had little effect on Type II spectral interaction of aniline, but noncompetitvely inhibited the Type I spectral interaction of benzphetamine and biphenyl. Whilst the mixed function oxidase enzyme inhibitors SKF 525A and metyrapone markedly reduced the metabolism of ethylmorphine and anailine, DMN demethylase was little affected by the former compound and appreciably enhanced by metyrapone. Moreover, DMN demethylase was strongly inhibited a number of hepatic mixed function oxidases, but significantly reduced anaerobic nitroreductase activity. The results of these studies reveal important differences between the properties of the enzymatic systems which metabolize DMN and mixed function oxidase substrates, and are consistent with the conclusion that the degradation of DMN to formaldehyde by rat liver preparations is a multicomponent system not rate limiting with respect to cytochrome P-450.
二甲基亚硝胺(DMN)向甲醛的生物转化,通常归因于与微粒体混合功能氧化酶系统相关的脱甲基酶的介导作用,已在大鼠肝脏制剂中进行了研究。所有酶活性均在后线粒体部分中发现,微粒体中含有约50%的这种活性。发现将胞质溶胶添加到微粒体部分后总活性的恢复是由于胞质溶胶中存在可扩散的、热不稳定成分。酶动力学研究表明,DMN通过多步或多组分过程代谢为甲醛。与细胞色素P-450和许多混合功能氧化酶活性相比,发现DMN脱甲基酶在储存时相对稳定。在光谱相互作用研究中,发现DMN与对照、苯巴比妥预处理或磷脂缺失的微粒体制剂形成非典型相互作用光谱。DMN对苯胺的II型光谱相互作用影响很小,但非竞争性抑制苄非他明和联苯的I型光谱相互作用。虽然混合功能氧化酶抑制剂SKF 525A和甲吡酮显著降低了乙基吗啡和苯胺的代谢,但DMN脱甲基酶受前一种化合物的影响很小,而甲吡酮可明显增强其活性。此外,DMN脱甲基酶受到多种肝脏混合功能氧化酶的强烈抑制,但显著降低了厌氧硝基还原酶活性。这些研究结果揭示了代谢DMN的酶系统与混合功能氧化酶底物的性质之间的重要差异,并且与以下结论一致:大鼠肝脏制剂将DMN降解为甲醛是一个多组分系统,相对于细胞色素P-450而言不是限速步骤。